Point72 Hong Kong LTD Atreca, Inc. Transaction History

Point72 Hong Kong LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.56 - $3.25 $1,723 - $3,591	-1,105 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $3,603 - $11,637	-2,238 Reduced 66.95%	1,105 $4,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $9,594 - $21,027	3,343 New	3,343 $10,000
Q3 2021 Nov 15, 2021	SELL	$4.91 - $9.07 $5,852 - $10,811	-1,192 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $9,321 - $16,449	1,192 New	1,192 $10,000
Q3 2019 Nov 14, 2019	SELL	$10.42 - $22.04 $79,785 - $168,760	-7,657 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$17.07 - $18.84 $130,704 - $144,257	7,657 New	7,657 $144,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.